Treatment for cognitive and neuropsychiatric non-motor symptoms in Parkinson’s disease: current evidence and future perspectives

References

• Lee A, Gilbert RM. Epidemiology of Parkinson disease. Neurol Clin. 2016;34:955–965.
   PubMed Web of Science ®Google Scholar
• Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124:901–905.
   PubMed Web of Science ®Google Scholar
• Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912.
   PubMed Web of Science ®Google Scholar
• Zaman V, Shields DC, Shams R, et al. Cellular and molecular pathophysiology in the progression of Parkinson’s disease. Metab Brain Dis. 2021;36(5):815–827.
   PubMed Web of Science ®Google Scholar
• Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–752.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464–474.
   PubMed Web of Science ®Google Scholar
• Politis M, Wu K, Loane C, et al. Staging of serotonergic dysfunction in Parkinson’s disease: an in vivo 11C-DASB PET study. Neurobiol Dis. 2010;40:216–221.
   PubMed Web of Science ®Google Scholar
• Gratwicke J, Jahanshahi M, Foltynie T. Parkinson’s disease dementia: a neural networks perspective. Brain. 2015;138:1454–1476.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–210.
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Synuclein deposition and non-motor symptoms in Parkinson disease. J Neurol Sci. 2011;310:107–111.
   PubMed Web of Science ®Google Scholar
• Barnum CJ, Tansey MG. Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson’s disease? Curr Neurol Neurosci Rep. 2012;12(4):350–358.
   PubMed Web of Science ®Google Scholar
• Felice VD, Quigley EM, Sullivan AM, et al. Microbiota-gut-brain signalling in Parkinson’s disease: implications for non-motor symptoms. Parkinsonism Relat Disord. 2016;27:1–8.
   PubMed Web of Science ®Google Scholar
• Kasten M, Marras C, Klein C. Nonmotor signs in genetic forms of Parkinson’s disease. Int Rev Neurobiol. 2017;133:129–178.
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Is Braak staging valid for all types of Parkinson’s disease? J Neural Transm (Vienna). 2019;126:423–431.
   PubMed Web of Science ®Google Scholar
• Hall JM, Lewis SJG. Neural correlates of cognitive impairment in Parkinson’s disease: a review of structural MRI findings. Int Rev Neurobiol. 2019;144:1–28.
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Morphological basis of Parkinson disease-associated cognitive impairment: an update. J Neural Transm (Vienna). 2022;129(8):977–999.
   PubMed Web of Science ®Google Scholar
• Salehi MA, Mohammadi S, Gouravani M, et al. Brain microstructural alterations of depression in Parkinson’s disease: a systematic review of diffusion tensor imaging studies. Hum Brain Mapp. 2022;43(18):5658–5680.
   PubMed Web of Science ®Google Scholar
• Carey G, Görmezoglu M, de Jong JJA, et al. Neuroimaging of anxiety in Parkinson’s disease: a systematic review. Mov Disord. 2020;36(2):327–339.
   PubMed Web of Science ®Google Scholar
• Antonini A, Barone P, Marconi R, et al. The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life. J Neurol. 2012;259(12):2621–2631.
   PubMed Web of Science ®Google Scholar
• Barone P, Erro R, Picillo M. Quality of life and nonmotor symptoms in Parkinson’s disease. Int Rev Neurobiol. 2017;133:499–516.
   PubMed Web of Science ®Google Scholar
• Chahine LM, Weintraub D, Hawkins KA, et al. Cognition in individuals at risk for Parkinson’s: Parkinson associated risk syndrome (PARS) study findings. Mov Disord. 2016;31(1):86–94.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Batzu L, Halliday GM, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. 2021;7(1):47.
   PubMed Web of Science ®Google Scholar
• Leroi I, McDonald K, Pantula H, et al. Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol. 2012;25(4):208–214.
   PubMed Web of Science ®Google Scholar
• Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord. 2014;29(2):195–202.
   PubMed Web of Science ®Google Scholar
• Oosterveld LP, Allen JC Jr, Reinoso G, et al. Prognostic factors for early mortality in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(3):226–230.
   PubMed Web of Science ®Google Scholar
• Goldman JG, Cognitive Impairment SE. Dementia in Parkinson Disease. Clin Geriatr Med. 2020;36(2):365–377.
   PubMed Web of Science ®Google Scholar
• Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):844–852.
   PubMed Web of Science ®Google Scholar
• Jessen F, Wiese B, Bachmann C, et al. Prediction of dementia by subjective memory impairment effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry. 2010;67:414–422.
   PubMed Web of Science ®Google Scholar
• van Harten AC, Mielke MM, Swenson-Dravis DM, et al. Subjective cognitive decline and risk of MCI. Neurology. 2018;91:e300–e312.
   PubMed Web of Science ®Google Scholar
• Baschi R, Nicoletti A, Restivo V, et al. Frequency and correlates of subjective memory complaints in Parkinson’s disease with and without mild cognitive impairment: data from the Parkinson’s disease cognitive impairment study. J Alzheimers Dis. 2018;63(3):1015–1024.
   PubMed Web of Science ®Google Scholar
• Chua CY, Koh MRE, Chia NS, et al. Subjective cognitive Complaints in early Parkinson’s disease patients with normal cognition are associated with affective symptoms. Parkinsonism Relat Disord. 2021;82:24–28.
   PubMed Web of Science ®Google Scholar
• Dujardin K, Duhamel A, Delliaux M, et al. Cognitive complaints in Parkinson’s disease: its relationship with objective cognitive decline. J Neurol. 2010;257(1):79–84.
   PubMed Web of Science ®Google Scholar
• Santangelo G, Vitale C, Trojano L, et al. Subthreshold depression and subjective cognitive complaints in Parkinson’s disease. Eur J Neurol. 2014;21(3):541–544.
   PubMed Web of Science ®Google Scholar
• Koster DP, Higginson CI, MacDougall EE, et al. Subjective cognitive complaints in Parkinson disease without dementia: a preliminary study. Appl Neuropsychol Adult. 2015;22(4):287–292.
   PubMed Web of Science ®Google Scholar
• Barbosa RP, Mendonça MD, Caetano AP, et al. Cognitive complaints in Parkinson’s disease patients: from subjective cognitive complaints to dementia and affective disorders. J Neural Transm (Vienna). 2019;126(10):1329–1335.
   PubMed Web of Science ®Google Scholar
• Han LL, Wang L, Xu ZH, et al. Disease progression in Parkinson’s disease patients with subjective cognitive complaint. Ann Clin Transl Neurol. 2021;8(10):2096–2104.
   PubMed Web of Science ®Google Scholar
• Hong JY, Lee JE, Sohn YH, et al. Neurocognitive and atrophic patterns in Parkinson’s disease based on subjective memory complaints. J Neurol. 2012;259(8):1706–1712.
   PubMed Web of Science ®Google Scholar
• Dupouy J, Ory-Magne F, Mekies C, et al. Cognitive complaint in early Parkinson’s disease: a pilot study. Acta Neurol Scand. 2018;137(1):59–66.
   PubMed Web of Science ®Google Scholar
• Oedekoven C, Egeri L, Jessen F, et al. Subjective cognitive decline in idiopathic Parkinson's disease: a systematic review. Ageing Res Rev. 2022;74:101508.
   PubMed Web of Science ®Google Scholar
• Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord. 2012;27:349–356.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75:1062–1069.
   PubMed Web of Science ®Google Scholar
• Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011;26:1814–1824.
   PubMed Web of Science ®Google Scholar
• Biundo R, Weis L, Facchini S, et al. Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. Parkinsonism Relat Disord. 2014;20:394–399.
   PubMed Web of Science ®Google Scholar
• Hobson P, Meara J. Mild cognitive impairment in Parkinson’s disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort. Int J Geriatr Psychiatry. 2015;30:1048–1055.
   PubMed Web of Science ®Google Scholar
• Galtier I, Nieto A, Lorenzo JN, et al. Mild cognitive impairment in Parkinson’s disease: diagnosis and progression to dementia. J Clin Exp Neuropsychol. 2016;38(1):40–50.
   PubMed Web of Science ®Google Scholar
• Federico A, Trentin M, Zanette G, et al. mild cognitive impairment in Parkinson’s disease: which tests perform best in the Italian population? Neurol Sci. 2017;38(8):1461–1468.
   PubMed Web of Science ®Google Scholar
• Martinez-Horta S, Kulisevsky J. Mild cognitive impairment in Parkinson’s disease. J Neural Transm (Vienna). 2019;126(7):897–904.
   PubMed Web of Science ®Google Scholar
• Wallace ER, Segerstrom SC, van Horne CG, et al. Meta-analysis of cognition in Parkinson’s disease mild cognitive impairment and dementia progression. Neuropsychol Rev. 2022;32(1):149–160.
   PubMed Web of Science ®Google Scholar
• Broeders M, de Bie RM, Velseboer DC, et al. Evolution of mild cognitive impairment in Parkinson disease. Neurology. 2013;81:346–352.
   PubMed Web of Science ®Google Scholar
• Pedersen KF, Larsen JP, Tysnes OB, et al. Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. Neurology. 2017;88(8):767–774.
   PubMed Web of Science ®Google Scholar
• Domellöf ME, Ekman U, Forsgren L, et al. Cognitive function in the early phase of Parkinson’s disease, a five-year follow-up. Acta Neurol Scand. 2015;132(2):79–88.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Simuni T, Caspell-Garcia C, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mov Disord. 2015;30(7):919–927.
   PubMed Web of Science ®Google Scholar
• Lawson RA, Yarnall AJ, Duncan GW, et al. Stability of mild cognitive impairment in newly diagnosed Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88(8):648–652.
   PubMed Web of Science ®Google Scholar
• Roberts R, Knopman DS. Classification and epidemiology of MCI. Clin Geriatr Med. 2013;29:753–772.
   PubMed Web of Science ®Google Scholar
• Baiano C, Barone P, Trojano L, et al. Prevalence and clinical aspects of mild cognitive impairment in Parkinson’s disease: a meta-analysis. Mov Disord. 2020;35(1):45–54.
   PubMed Web of Science ®Google Scholar
• Hoogland J, Boel JA, de Bie RMA, et al. Mild cognitive impairment as a risk factor for Parkinson’s disease dementia: MCI as a risk factor for Parkinson’s disease dementia. Mov Disord. 2017;32:1056–1065.
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689–1707. quiz 1837.
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009 Nov;132(Pt 11):2958–2969.
   PubMed Web of Science ®Google Scholar
• Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70(13):1017–1022.
   PubMed Web of Science ®Google Scholar
• Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–844.
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013;84(11):1258–1264.
   PubMed Web of Science ®Google Scholar
• Kempster PA, O’Sullivan SS, Holton JL, et al. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain. 2010;133(pt6):1755Y1762.
   Google Scholar
• Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74:885–892.
   PubMed Web of Science ®Google Scholar
• Perez F, Helmer C, Foubert-Samier A, et al. Risk of dementia in an elderly population of Parkinson’s disease patients: a 15-year population-based study. Alzheimers Dement. 2012;8(6):463–469.
   PubMed Web of Science ®Google Scholar
• Cholerton BA, Zabetian CP, Quinn JF, et al. Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Parkinsons Dis. 2013;3(2):205–214.
   PubMedGoogle Scholar
• Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13:217–231.
   PubMed Web of Science ®Google Scholar
• Locascio JJ, Corkin S, Growdon JH. Relation between clinical characteristics of Parkinson’s disease and cognitive decline. J Clin Exp Neuropsychol. 2003;25(1):94Y109.
   Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387–392.
   PubMedGoogle Scholar
• Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology. 2000;54(8):1596Y1602.
   Web of Science ®Google Scholar
• Uc EY, McDermott MP, Marder KS, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology. 2009;73(18):1469Y1477.
   Web of Science ®Google Scholar
• Marinus J, Zhu K, Marras C, et al. Risk factors for non-motor symptoms in Parkinson’s disease. Lancet Neurol. 2018;17(6):559–568.
   PubMed Web of Science ®Google Scholar
• Lichter DG, Benedict RHB, Hershey LA. Importance of balance-gait disorder as a risk factor for cognitive impairment, dementia and related non-motor symptoms in Parkinson’s disease. J Parkinsons Dis. 2018;8(4):539–552.
   PubMedGoogle Scholar
• Skorvanek M, Goldman JG, Jahanshahi M, et al. Global scales for cognitive screening in Parkinson’s disease: critique and recommendations. Mov Disord. 2018;33(2):208–218.
   PubMed Web of Science ®Google Scholar
• Castrioto A, Thobois S, Carnicella S, et al. Emotional manifestations of PD: neurobiological basis. Mov Disord. 2016;31(8):1103–1113.
   PubMed Web of Science ®Google Scholar
• Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435–450. Erratum in: Nat Rev Neurosci. 2017;18(8):509.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Aarsland D, Chaudhuri KR, et al. The neuropsychiatry of Parkinson’s disease: advances and challenges. Lancet Neurol. 2022;21(1):89–102.
   PubMed Web of Science ®Google Scholar
• Martínez-Fernández R, Schmitt E, Martinez-Martin P, et al. The hidden sister of motor fluctuations in Parkinson’s disease: a review on nonmotor fluctuations. Mov Disord. 2016;31(8):1080–1094.
   PubMed Web of Science ®Google Scholar
• Cong S, Xiang C, Zhang S, et al. Prevalence and clinical aspects of depression in Parkinson’s disease: a systematic review and meta-analysis of 129 studies. Neurosci Biobehav Rev. 2022;21:104749.
   Google Scholar
• Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2015;30(12):1600–1611.
   PubMed Web of Science ®Google Scholar
• Kritzinger C, Vollstedt EJ, Hückelheim K, et al. Qualitative characteristics of depression in Parkinson’s patients and controls. Behav Neurol. 2015;2015:961372.
   PubMed Web of Science ®Google Scholar
• Alzahrani H, Venneri A. Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson’s disease: a systematic review. J Neurol Sci. 2015;356(1–2):32–44.
   PubMed Web of Science ®Google Scholar
• Qamar MA, Sauerbier A, Politis M, et al. Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis? NPJ Parkinsons Dis. 2017;3:5.
   PubMed Web of Science ®Google Scholar
• Galts CPC, Bettio LEB, Jewett DC, et al. Depression in neurodegenerative diseases: common mechanisms and current treatment options. Neurosci Biobehav Rev. 2019;102:56–84.
   PubMed Web of Science ®Google Scholar
• Broen MP, Narayen NE, Kuijf ML, et al. Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2016;31(8):1125–1133.
   PubMed Web of Science ®Google Scholar
• Clark AJ, Ritz B, Prescott E, et al. Psychosocial risk factors, pre-motor symptoms and first-time hospitalization with Parkinson’s disease: a prospective cohort study. Eur J Neurol. 2013;20:1113–1120.
   PubMed Web of Science ®Google Scholar
• Schrag A, Horsfall L, Walters K, et al. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 2015;14:57–64.
   PubMed Web of Science ®Google Scholar
• Schrag A, Taddei RN. Depression and anxiety in Parkinson’s disease. Int Rev Neurobiol. 2017;133:623–655.
   PubMed Web of Science ®Google Scholar
• van der Velden RMJ, Broen MPG, Kuijf ML, et al. Frequency of mood and anxiety fluctuations in Parkinson’s disease patients with motor fluctuations: a systematic review. Mov Disord. 2018;33:1521–1527.
   PubMed Web of Science ®Google Scholar
• Fenelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci. 2010;289(1–2):12–17.
   PubMed Web of Science ®Google Scholar
• Ffytche DH, Creese B, Politis M, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017;13(2):81–95.
   PubMed Web of Science ®Google Scholar
• Frei K, Truong DD. Hallucinations and the spectrum of psychosis in Parkinson’s disease. J Neurol Sci. 2017;374:56–62.
   PubMed Web of Science ®Google Scholar
• Marin RS. Apathy: concept, syndrome, neural mechanisms, and treatment. Semin Clin Neuropsychiatry. 1996;1:304–314.
   PubMedGoogle Scholar
• Pagonabarraga J, Kulisevsky J. Apathy in Parkinson’s Disease. Int Rev Neurobiol. 2017;133:657–678. .
   PubMed Web of Science ®Google Scholar
• De Waele S, Cras P, Crosiers D. Apathy in Parkinson’s disease: defining the park apathy subtype. Brain Sci. 2022;12(7):923.
   PubMed Web of Science ®Google Scholar
• Baggio HC, Segura B, Garrido-Millan JL, et al. Resting-state frontostriatal functional connectivity in Parkinson’s disease-related apathy. Mov Disord. 2015;30:671–679.
   PubMed Web of Science ®Google Scholar
• Thobois S, Prange S, Sgambato-Faure V, et al. Imaging the etiology of apathy, anxiety, and depression in Parkinson’s disease: implication for treatment. Curr Neurol Neurosci Rep. 2017;17(10):76.
   PubMed Web of Science ®Google Scholar
• Snaith RP, Hamilton M, Morley S, et al. A scale for the assessment of hedonic tone: the Snaith-Hamilton pleasure scale. Br J Psychiatry. 1995;167:99–103.
   PubMed Web of Science ®Google Scholar
• Assogna F, Cravello L, Caltagirone C, et al. Anhedonia in Parkinson’s disease: a systematic review of the literature. Mov Disord. 2011;26(10):1825–1834.
   PubMed Web of Science ®Google Scholar
• Nagayama H, Maeda T, Uchiyama T, et al. Anhedonia and its correlation with clinical aspects in Parkinson’s disease. J Neurol Sci. 2017;372:403–407.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Claassen DO. Impulse control and related disorders in Parkinson’s disease. Int Rev Neurobiol. 2017;133:679–717. .
   PubMed Web of Science ®Google Scholar
• Erga AH, Alves G, Larsen JP, et al. Impulsive and compulsive behaviors in Parkinson’s Disease: the Norwegian ParkWest study. J Parkinsons Dis. 2017;7(1):183–191.
   PubMedGoogle Scholar
• Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018;91:e189–e201.
   PubMed Web of Science ®Google Scholar
• Markovic V, Stankovic I, Petrovic I, et al. Dynamics of impulsive-compulsive behaviors in early Parkinson’s disease: a prospective study. J Neurol. 2020;267(4):1127–1136.
   PubMed Web of Science ®Google Scholar
• Martini A, Tamburin S, Biundo R, et al. Incentive-driven decision-making networks in de novo and drug-treated Parkinson’s disease patients with impulsive-compulsive behaviors: a systematic review of neuroimaging studies. Parkinsonism Relat Disord. 2020;78:165–177.
   PubMed Web of Science ®Google Scholar
• Teixeira AL others. Akathisia’. In: Movement disorders in psychiatry (New York, 2022; online edn, Oxford academic, 1 Sept. 2022) , Teixeira A, Stimming EF, Ondo WG, editors. cited 19 Jan. 2023. p. 69–119.https://doi.org/10.1093/med/9780197574317.003.0004
   Google Scholar
• Martini A, Dal Lago D, Edelstyn NMJ, et al. Impulse control disorder in Parkinson’s disease: a meta-analysis of cognitive, affective, and motivational correlates. Front Neurol. 2018a;9:654.
   PubMed Web of Science ®Google Scholar
• Martini A, Dal Lago D, Edelstyn NMJ, et al. Dopaminergic neurotransmission in patients with Parkinson’s disease and impulse control disorders: a Systematic review and meta-analysis of PET and SPECT studies. Front Neurol. 2018b;9:1018.
   PubMed Web of Science ®Google Scholar
• Braude WM, Barnes TR, Gore SM. Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry. 1983;143:139–150.
   PubMed Web of Science ®Google Scholar
• Lang AE, Johnson K. Akathisia in idiopathic Parkinson’s disease. Neurology. 1987;37:477–481.
   PubMed Web of Science ®Google Scholar
• Comella CL, Goetz CG. Akathisia in Parkinson’s disease. Mov Disord. 1994;9(5):545–549.
   PubMedGoogle Scholar
• Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology. 2002;59(3):408–413.
   PubMed Web of Science ®Google Scholar
• Aykaç O, Durmaz Çelik FN, Yilmaz R, et al. Akathisia in Parkinson’s disease: a comparative cross-sectional study. Turk J Neurol. 2022;28:10–13.
   Web of Science ®Google Scholar
• Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A, et al. The clinical challenges of akathisia. CNS Spectr. 2015;20(1):1–14;quiz:15–16.
   Google Scholar
• LeWitt PA, Chaudhuri KR. Unmet needs in Parkinson disease: motor and non-motor. Parkinsonism Relat Disord. 2020;80(1):S7–S12. .
   PubMedGoogle Scholar
• Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180–198. Erratum in: Mov Disord. 2019;34(5):765.
   PubMed Web of Science ®Google Scholar
• Karanth S, Nelson PT, Katsumata Y, et al. Prevalence and clinical phenotype of quadruple misfolded proteins in older adults. JAMA Neurol. 2020;77(10):1299–1307.
   PubMed Web of Science ®Google Scholar
• Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;2012(3):CD006504.
   PubMedGoogle Scholar
• Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135–143.
   PubMed Web of Science ®Google Scholar
• Leroi I, Overshott R, Byrne EJ, et al. Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Mov Disord. 2009;24(8):1217–1221.
   PubMed Web of Science ®Google Scholar
• Stubendorff K, Larsson V, Ballard C, et al. Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson’s disease with dementia: a prospective study. BMJ Open. 2014;4(7):e005158.
   PubMed Web of Science ®Google Scholar
• Brennan L, Pantelyat A, Duda JE, et al. Memantine and cognition in Parkinson’s disease dementia/dementia with Lewy bodies: a meta-analysis. Mov Disord Clin Pract. 2015;3(2):161–167.
   PubMed Web of Science ®Google Scholar
• Tsuboi T, Satake Y, Hiraga K, et al. Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: a systematic review. NPJ Parkinsons Dis. 2022;8(1):75.
   PubMed Web of Science ®Google Scholar
• Zucchella C, Sinforiani E, Tamburin S, et al. The multidisciplinary approach to Alzheimer’s disease and dementia. A narrative review of non-pharmacological treatment. Front Neurol. 2018;9:1058.
   PubMed Web of Science ®Google Scholar
• Bahar-Fuchs A, Martyr A, Goh AM, et al. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev. 2019;3(3):CD013069.
   PubMedGoogle Scholar
• Orgeta V, McDonald KR, Poliakoff E, et al. Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2020;2(2):CD011961.
   PubMedGoogle Scholar
• Couture M, Giguère-Rancourt A, Simard M. The impact of cognitive interventions on cognitive symptoms in idiopathic Parkinson’s disease: a systematic review. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2019;26(5):637–659.
   PubMed Web of Science ®Google Scholar
• Gavelin HM, Domellöf ME, Leung I, et al. Computerized cognitive training in Parkinson’s disease: a systematic review and meta-analysis. Ageing Res Rev. 2022;80:101671.
   PubMed Web of Science ®Google Scholar
• Loetscher T. Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s disease - A Cochrane review summary with commentary. NeuroRehabilitation. 2021;48(3):385–387.
   PubMed Web of Science ®Google Scholar
• Dinkelbach L, Brambilla M, Manenti R, et al. Non-invasive brain stimulation in Parkinson’s disease: exploiting crossroads of cognition and mood. Neurosci Biobehav Rev. 2017;75:407–418.
   PubMed Web of Science ®Google Scholar
• Pupíková M, Rektorová I. Non-pharmacological management of cognitive impairment in Parkinson’s disease. J Neural Transm (Vienna). 2020;127(5):799–820.
   PubMed Web of Science ®Google Scholar
• Sanches C, Stengel C, Godard J, et al. Past, present, and future of non-invasive brain stimulation approaches to treat cognitive impairment in neurodegenerative diseases: time for a comprehensive critical review. Front Aging Neurosci. 2021;12:578339.
   PubMed Web of Science ®Google Scholar
• Marson F, Lasaponara S, Cavallo M, et al. Review of neuromodulation techniques in neurodegenerative diseases: a useful tool for clinical practice? Medicina (Kaunas). 2021;57(3):215.
   PubMed Web of Science ®Google Scholar
• Isaacs KR, Anderson BJ, Alcantara AA, et al. Exercise and the brain: angiogenesis in the adult rat cerebellum after vigorous physical activity and motor skill learning. J Cereb Blood Flow Metab. 1992;12(1):110–119. Erratum in: J Cereb Blood Flow Metab 1992;12(3):533.
   PubMed Web of Science ®Google Scholar
• Churchill JD, Galvez R, Colcombe S, et al. Exercise, experience and the aging brain. Neurobiol Aging. 2002;23(5):941–955.
   PubMed Web of Science ®Google Scholar
• Vaynman S, Gomez-Pinilla F. Revenge of the “sit”: how lifestyle impacts neuronal and cognitive health through molecular systems that interface energy metabolism with neuronal plasticity. J Neurosci Res. 2006;84(4):699–715.
   PubMed Web of Science ®Google Scholar
• Norton S, Matthews FE, Barnes DE, et al. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788–794.
   PubMed Web of Science ®Google Scholar
• Stuckenschneider T, Askew CD, Menêses AL, et al. The effect of different exercise modes on domain-specific cognitive function in patients suffering from Parkinson’s disease: a systematic review of randomized controlled trials. J Parkinsons Dis. 2019;9(1):73–95.
   PubMedGoogle Scholar
• Wang XL, Feng ST, Wang YT, et al. Comparative efficacy and acceptability of drug treatments for Parkinson’s disease with depression: a systematic review with network meta-analysis. Eur J Pharmacol. 2022;927:175070.
   PubMed Web of Science ®Google Scholar
• Webster P. Pimavanserin evaluated by the FDA. Lancet. 2018;391:1762.
   PubMed Web of Science ®Google Scholar
• Iketani R, Furushima D, Imai S, et al. Efficacy and safety of atypical antipsychotics for psychosis in Parkinson’s disease: a systematic review and Bayesian network meta-analysis. Parkinsonism Relat Disord. 2020;78:82–90.
   PubMed Web of Science ®Google Scholar
• Meloni M, Puligheddu M, Carta M, et al. Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson’s disease: a preliminary finding. Eur J Neurol. 2020;27(5):779–786.
   PubMed Web of Science ®Google Scholar
• Schneider RB, Auinger P, Tarolli CG, et al. A trial of buspirone for anxiety in Parkinson’s disease: safety and tolerability. Parkinsonism Relat Disord. 2020;81:69–74.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Jitkritsadakul O, Friedman JH, et al. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67–75.
   PubMed Web of Science ®Google Scholar
• APA. cited 1 Dec 2022. https://dictionary.apa.org/cognitive-behavior-therapy
   Google Scholar
• Kampling H, Brendel LK, Mittag O. (Neuro)psychological interventions for non-motor symptoms in the treatment of patients with Parkinson’s disease: a systematic umbrella review. Neuropsychol Rev. 2019;29(2):166–180.
   PubMed Web of Science ®Google Scholar
• Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014-2018). Clin Neurophysiol. 2020;131(2):474–528. Erratum in: Clin Neurophysiol. 2020;131(5):1168-1169.
   PubMed Web of Science ®Google Scholar
• Brys M, Fox MD, Agarwal S, et al. Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: a randomized trial. Neurology. 2016;87:1907–1915.
   PubMed Web of Science ®Google Scholar
• Makkos A, Pál E, Aschermann Z, et al. High-Frequency repetitive transcranial magnetic stimulation can improve depression in Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Neuropsychobiology. 2016;73:169–177.
   PubMed Web of Science ®Google Scholar
• Wei W, Yi X, Ruan J, et al. The efficacy of repetitive transcranial magnetic stimulation on emotional processing in apathetic patients with Parkinson’s disease: a Placebo-controlled ERP study. J Affect Disord. 2021;282:776–785.
   PubMed Web of Science ®Google Scholar
• Zucchella C, Mantovani E, Federico A, et al. Non-invasive brain stimulation for gambling disorder: a systematic review. Front Neurosci. 2020;14:729.
   PubMed Web of Science ®Google Scholar
• Moonen AJH, Mulders AEP, Defebvre L, et al. Cognitive behavioral therapy for anxiety in Parkinson’s disease: a randomized controlled trial. Mov Disord. 2021;36(11):2539–2548.
   PubMed Web of Science ®Google Scholar
• Zumkehr J, Rodriguez-Ortiz CJ, Cheng D, et al. Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer’s disease. Neurobiol Aging. 2015;36(7):2260–2271.
   PubMed Web of Science ®Google Scholar
• Tikhonova MA, Ho SC, Akopyan AA, et al. Neuroprotective effects of ceftriaxone treatment on cognitive and neuronal deficits in a rat model of accelerated senescence. Behav Brain Res. 2017;330:8–16.
   PubMed Web of Science ®Google Scholar
• Vossel K, Ranasinghe KG, Beagle AJ, et al. Effect of levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial. JAMA Neurol. 2021;78(11):1345–1354.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yang C, Liu T, et al. Citalopram restores short-term memory deficit and non-cognitive behaviors in APP/PS1 mice while halting the advance of Alzheimer’s disease-like pathology. Neuropharmacology. 2018;131:475–486.
   PubMed Web of Science ®Google Scholar
• Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson’s disease. J Parkinsons Dis. 2013;3(4):461–491.
   PubMedGoogle Scholar
• Silveira CRA, MacKinley J, Coleman K, et al. Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurol. 2019;19(1):20.
   PubMedGoogle Scholar
• Moore TJ, Alami A, Alexander GC, et al. Safety and effectiveness of NMDA receptor antagonists for depression: a multidisciplinary review. Pharmacotherapy. 2022;42(7):567–579.
   PubMed Web of Science ®Google Scholar
• Tsitsipa E, Rogers J, Casalotti S, et al. Selective 5HT3 antagonists and sensory processing: a systematic review. Neuropsychopharmacology. 2022;47(4):880–890.
   PubMed Web of Science ®Google Scholar
• Lang AE, Siderowf AD, Macklin EA, et al. Trial of cinpanemab in early Parkinson’s disease. N Engl J Med. 2022;387(5):408–420.
   PubMed Web of Science ®Google Scholar
• Wamelen DJV, Rukavina K, Podlewska AM, et al. Advances in the pharmacological and non-pharmacological management of non-motor symptoms in Parkinson’s disease: an update since 2017. Curr Neuropharmacol. 2022.
   PubMedGoogle Scholar
• Mantovani E, Zucchella C, Bottiroli S, et al. Telemedicine and virtual reality for cognitive rehabilitation: a roadmap for the COVID-19 pandemic. Front Neurol. 2020;11:926.
   PubMed Web of Science ®Google Scholar
• Cummings J, Lee G, Nahed P, et al. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022;8(1):e12295.
   PubMedGoogle Scholar
• Nielsen J, Young C, Ifteni P, et al. Worldwide differences in regulations of clozapine use. CNS Drugs. 2016;30(2):149–161.
   PubMed Web of Science ®Google Scholar
• Mosholder AD, Ma Y, Akhtar S, et al. Mortality among Parkinson’s disease patients treated with pimavanserin or atypical antipsychotics: an observational study in medicare beneficiaries. Am J Psychiatry. 2022;179(8):553–561.
   PubMed Web of Science ®Google Scholar
• Crippa JAS, Hallak JEC, Zuardi AW, et al. Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms? Eur Arch Psychiatry Clin Neurosci. 2019;269(1):121–133.
   PubMed Web of Science ®Google Scholar